Osteopenia: what a low bone density result means

Osteopenia means your bone density is lower than that of a healthy young adult but not low enough to be called osteoporosis: a T-score between -1.0 and -2.5. It is common after menopause and is a signal to look at your overall fracture risk, not a diagnosis that automatically needs medication. Many women with osteopenia need only exercise, good nutrition and a plan for the next scan; some, because of age or other risk factors, benefit from treatment.

How bone density is scored

A DXA scan measures mineral density at the hip and lower spine. The result is compared with a young-adult reference to give a T-score, using the World Health Organization categories:

T-score	Category	What it means
-1.0 or higher	Normal	Within the young-adult range
Between -1.0 and -2.5	Low bone mass (osteopenia)	Lower than young adults; fracture risk depends on other factors
-2.5 or lower	Osteoporosis	Diagnosed by density alone

For adults between 20 and 50, the International Society for Clinical Densitometry recommends a Z-score instead, which compares you with people your own age; a Z-score of -2.0 or lower is called low for age.

Low bone mass is common. Based on national survey data, the Bone Health and Osteoporosis Foundation has estimated that 43.4 million Americans have low bone density, in addition to those with osteoporosis.

Why the number is not the whole story

A low T-score raises fracture risk, but most fractures do not happen in women with osteoporosis-range scores. The Bone Health and Osteoporosis Foundation’s clinician guide notes that the majority of fractures occur in people with T-scores better than -2.5, because falls, frailty and bone quality also matter.

The scale of this was shown in a US study of 149,524 white postmenopausal women aged 50 to 104. Over one year, 2,259 reported a new fracture. Women with T-scores of -2.5 or lower had the highest fracture rates but accounted for only 18% of fractures and 26% of hip fractures. Overall, 82% of the women who broke a bone had T-scores better than -2.5. The study used peripheral devices at the heel, finger or forearm rather than hip DXA, but the lesson holds: many women with osteopenia are at meaningful risk, and many are not.

That is why clinicians use FRAX, a calculator that combines your femoral neck bone density with age, body mass index, prior fracture, a parent’s hip fracture, smoking, steroid use, rheumatoid arthritis, alcohol (3 or more drinks a day) and causes of secondary bone loss such as menopause before 40. It returns your 10-year probability of a hip fracture and of a major osteoporotic fracture.

When treatment is recommended

The Bone Health and Osteoporosis Foundation suggests considering medication for postmenopausal women with:

Situation	Treatment considered?
Hip or spine fracture, at any bone density	Yes
T-score of -2.5 or lower at the hip or spine	Yes
Osteopenia at the hip with FRAX 10-year hip fracture risk of 3% or more	Yes
Osteopenia at the hip with FRAX 10-year major fracture risk of 20% or more	Yes
Fracture of the upper arm, pelvis or wrist with osteopenia	Yes
Osteopenia with FRAX below both thresholds	Usually lifestyle measures and monitoring

What the trials show for osteopenia. In a New Zealand trial, 2,000 women aged 65 and older with osteopenia at the hip received four infusions of zoledronate (a bisphosphonate) or saline, one every 18 months, over 6 years. Their average femoral neck T-score was -1.6 and their median 10-year hip fracture risk was 2.3%, below the usual US threshold. Fragility fractures occurred in 190 women on placebo and 122 on zoledronate (hazard ratio 0.63). Fifteen women needed treatment to prevent one fracture.

A second trial, published in 2025, enrolled 1,054 women aged 50 to 60 with T-scores between 0 and -2.5. Those given zoledronate at the start and again at 5 years had new spine fractures on X-ray in 6.3% over 10 years, compared with 11.1% with placebo (relative risk 0.56). A single dose at the start also reduced fractures of any kind and major osteoporotic fractures. This is one trial in a largely low-risk group, so ask whether it applies to you rather than expecting infrequent treatment to be offered routinely.

What you can do now

Strength and impact training. In the LIFTMOR trial, 101 postmenopausal women with T-scores below -1.0 did either 8 months of supervised, twice-weekly high-intensity resistance and impact training or a low-intensity home program. Spine bone density rose 2.9% with training and fell 1.2% in the home group; hip density rose 0.3% versus a 1.9% loss, and physical function improved. Start under supervision. See weight training and bone density.

Calcium and vitamin D in the right amounts. Aim for 1,200 mg of calcium a day from age 51, mostly from food, and 800 to 1,000 IU of vitamin D after 50, per the Bone Health and Osteoporosis Foundation. Our vitamin D guide explains what the big trials found.

Prevent falls. Most fractures in older adults follow a fall, and falls occur in about a third of adults 65 and older. Treat vision problems, review sedating medications, improve home lighting and add balance training.

Check for secondary causes. A clinician may order blood tests such as calcium, kidney and liver function, vitamin D and parathyroid hormone, and review medications that weaken bone, such as long-term steroids, aromatase inhibitors and excess thyroid hormone.

Plan the next scan. The Bone Health and Osteoporosis Foundation says less frequent testing is reasonable for T-scores in the normal or mildly low range. The USPSTF notes that cohort studies found repeating a scan at an interval of 4 to 8 years did not improve fracture prediction. Women 65 and older with a T-score of -1.0 or lower may also be offered spine imaging to look for silent vertebral fractures.

Where hormone therapy fits

Estrogen is FDA-approved to prevent postmenopausal osteoporosis, so for a woman in her late 40s or 50s with osteopenia and bothersome hot flashes, hormone therapy can serve both purposes. When the only goal is fracture prevention, the FDA advises considering approved non-estrogen medications first. Bone loss resumes after stopping estrogen. For the risk-benefit balance by age, see is hormone therapy safe? and our guide to preventing osteoporosis.

When to see a clinician

• You have osteopenia and have never had a FRAX estimate.
• You broke a bone in a fall from standing height or less.
• You have lost height or have new back pain.
• You take steroids, an aromatase inhibitor or another bone-depleting medicine.
• Your Z-score was low before menopause, which calls for a search for an underlying cause.

An endocrinologist or a menopause specialist can help when the decision about medication is close. You can find one through our directory.